Report from the World Health Organization's immunization and vaccines-related implementation research advisory committee (IVIR-AC) ad hoc meeting, 28 June - 1 July 2024.

Autor: Lambach P; Immunizations, Vaccines and Biologicals, World Health Organization, Geneva, Switzerland., Silal S; Modelling and Simulation Hub, Africa, University of Cape Town, Cape Town, South Africa; Centre for Global Health, Nuffield Department of Medicine, Oxford University, Oxford, United Kingdom., Sbarra AN; Johns Hopkins Bloomberg School of Public Health, Baltimore, United States. Electronic address: asbarra1@jhu.edu., Crowcroft NS; Immunizations, Vaccines and Biologicals, World Health Organization, Geneva, Switzerland., Frey K; Institute for Disease Modeling, Bill & Melinda Gates Foundation, Seattle, United States., Ferrari M; Pennsylvania State University, State College, United States., Vynnycky E; UKHSA, London, United Kingdom; London School of Hygiene & Tropical Medicine, London, United Kingdom., Metcalf CJE; Department of Ecology and Evolutionary Biology, Princeton University, Princeton, United States., Winter AK; Department of Epidemiology and Biostatistics & Center for the Ecology of Infectious Diseases, University of Georgia, Athens, United States., Zimmerman L; Centers for Disease Control and Prevention, Atlanta, United States., Koh M; Immunizations, Vaccines and Biologicals, World Health Organization, Geneva, Switzerland., Sheel M; School of Public Health, Faculty of Medicine and Health, University of Sydney, Sydney, Australia; Sydney Infectious Diseases Institute, Faculty of Medicine and Health, University of Sydney, Sydney, Australia., Kim SY; Seoul National University, Seoul, South Korea., Munywoki PK; Kenya Medical Research Institute, Centre for Global Health Research, Nairobi, Kenya., Portnoy A; Department of Global Health, Boston University School of Public Health, Boston, United States; Center for Health Decision Science, Harvard T.H. Chan School of Public Health, Boston, United States., Aggarwal R; Jawaharlal Institute of Postgraduate Medical Education & Research, Puducherry, India., Farooqui HH; College of Medicine, QU Health, Qatar University., Flasche S; Centre for Global Health, Charite, Berlin, Germany., Hogan AB; School of Population Health, University of New South Wales, Sydney, Australia., Leung K; School of Public Health, The University of Hong Kong, Hong Kong SAR, China., Moss WJ; Johns Hopkins Bloomberg School of Public Health, Baltimore, United States., Wang XY; Shanghai Institute of Infectious Disease and Biosecurity, Fudan University, Shanghai, China.
Jazyk: angličtina
Zdroj: Vaccine [Vaccine] 2024 Dec 02; Vol. 42 (26), pp. 126307. Date of Electronic Publication: 2024 Sep 14.
DOI: 10.1016/j.vaccine.2024.126307
Abstrakt: The World Health Organization's Immunization and Vaccines-related Implementation Research Advisory Committee (IVIR-AC) serves to independently review and evaluate vaccine-related research to maximize the potential impact of vaccination programs. From 28 June - 1 July 2024, IVIR-AC was convened for an ad hoc meeting to discuss new evidence on criteria for rubella vaccine introduction and the risk of congenital rubella syndrome. This report summarizes background information on rubella virus transmission and the burden of congenital rubella syndrome, meeting structure and presentations, proceedings, and recommendations.
Competing Interests: Declaration of competing interest P. L. was supported by the Bill & Melinda Gates Foundation for this work. S. S. was supported by the World Health Organization for this work. A. N. S. was financially supported by the World Health Organization for this work, and is additionally supported by the Bill & Melinda Gates Foundation, Gavi, the Vaccine Alliance, and the National Institutes of Health. K. F. is employed by the Bill & Melinda Gates Foundation. M. F. is supported by the National Science Foundation, the Bill & Melinda Gates Foundation, Gavi, the Vaccine Alliance, Centers for Disease Control and Prevention, and Imperial College London. E. V. was supported for this work by Gavi, the Vaccine Alliance via the Vaccine Impact Modeling Consortium (VIMC), which is jointly funded by Gavi, the Vaccine Alliance and the Bill & Melinda Gates Foundation. C. J. E. M. has previously received travel funds to visit the Max Plank Institute of Evolutionary Anthropology. A. K. W. was supported for this work by Gavi, the Vaccine Alliance, is additionally supported by the Bill & Melinda Gates Foundation, and has previously received travel funds from Gavi, the Vaccine Alliance. M. K. was supported for this work by the Bill & Melinda Gates Foundation. A. P. is supported by Gavi, the Vaccine Alliance, Imperial College London, the Bill & Melinda Gates Foundation, and the World Health Organization. A. B. H. was supported by the Australian National Health and Medical Research Council for this work, is additionally supported by the Australian NSW Ministry of Health, PATH, the World Health Organization, and Gavi, the Vaccine Alliance, and has received consulting fees from the Australian NSW Ministry of Health, WHO Europe and Asian Development Bank. A. N. S. and M. F. report travel related support from the World Health Organization to attend previous IVIR-AC meetings. All other authors have no declarations.
(Copyright © 2024. Published by Elsevier Ltd.)
Databáze: MEDLINE
Externí odkaz: